levetiracetam + Placebo + Levetriracetam

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Traumatic Stress Disorder

Conditions

Post-Traumatic Stress Disorder

Trial Timeline

Nov 1, 2005 → Mar 1, 2008

About levetiracetam + Placebo + Levetriracetam

levetiracetam + Placebo + Levetriracetam is a phase 2/3 stage product being developed by UCB for Post-Traumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00413296. Target conditions include Post-Traumatic Stress Disorder.

What happened to similar drugs?

3 of 7 similar drugs in Post-Traumatic Stress Disorder were approved

Approved (3) Terminated (3) Active (1)
Galcanezumab-GnlmEli LillyApproved
Tramadol + PlaceboBrain BiotechApproved
Zoloft (Sertraline)PfizerPhase 3
Placebo + BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00413296Phase 2/3Completed

Competing Products

16 competing products in Post-Traumatic Stress Disorder

See all competitors
ProductCompanyStageHype Score
Galcanezumab-GnlmEli LillyApproved
43
Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3
40
Rizatriptan + PlaceboMerckPre-clinical
18
AMG 334NovartisPhase 2
35
Balovaptan + PlaceboRochePhase 2
35
ErenumabAmgenPhase 2
35
PF-04457845 + PlaceboPfizerPhase 2
27
Zoloft (Sertraline)PfizerPhase 3
32
Levetiracetam + PlaceboUCBPhase 3
32
Placebo + BrexpiprazoleLundbeckPhase 3
29
Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching PlaceboLundbeckPhase 2
32
AbobotulinumtoxinA + Normal salineIpsenApproved
40
Nabiximols + PlaceboJazz PharmaceuticalsPhase 2/3
27
60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114Praxis Precision MedicinesPhase 2
24
MDMANautilus BiotechnologyPhase 2
50
Tramadol + PlaceboBrain BiotechApproved
33